Core Viewpoint - Sanbo Brain Science aims to enhance its hospital management capabilities and clinical diagnosis levels while leveraging capital markets for investment in brain science-related medical equipment and pharmaceuticals [1] Investment Strategy - The company plans to establish a limited partnership focusing on brain science, primarily investing in next-generation medical devices, consumables, and drugs for the diagnosis and treatment of brain diseases [1] - Priority will be given to investing in early-stage small and medium enterprises located in the Changping area [1]

Core Viewpoint - The company, Zhaoyan New Drug (603127), has approved an investment of up to 8 million RMB in a private equity fund focused on brain science and related medical technologies [1] Investment Details - The investment will be made through the company's wholly-owned subsidiary, Beijing Zhaoyan Management Technology Co., Ltd., in collaboration with Beijing Chongde Yingsheng Investment Management Co., Ltd. and other partners [1] - The fund will primarily invest in new-generation medical devices, consumables, and drugs for the diagnosis and treatment of brain diseases [1] - The fund aims to prioritize investments in early-stage small and medium-sized enterprises located in the Changping area, with at least 50% of the total investment amount allocated to these enterprises [1]

Core Viewpoint - The company, Zhaoyan New Drug (06127), has approved an investment of up to 8 million RMB in a private equity fund focused on brain science and related medical technologies [1] Investment Details - The investment will be made through the company's wholly-owned subsidiary, Beijing Zhaoyan Management Technology Co., Ltd., in collaboration with Beijing Chongde Yingsheng Investment Management Co., Ltd. and other partners [1] - The fund will primarily invest in new-generation medical devices, consumables, and drugs for the diagnosis and treatment of brain diseases [1] - The fund aims to prioritize investments in early-stage small and medium-sized enterprises located in the Changping area, with at least 50% of the total investment amount allocated to these enterprises [1]